Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.

Autor: Drozd-Sokolowska J; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Dwilewicz-Trojaczek J; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Tormanowska M; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland; Department of Hematopoietic Stem Cell Transplantation, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Karakulska-Prystupiuk E; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Sachs W; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Halaburda K; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland; Department of Hematopoietic Stem Cell Transplantation, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Urbanowska E; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Gierej B; Department of Pathomorphology, Medical University of Warsaw, Poland., Basak GW; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland., Wiktor-Jedrzejczak W; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland. Electronic address: wieslaw.jedrzejczak@wum.edu.pl.
Jazyk: angličtina
Zdroj: Transplantation proceedings [Transplant Proc] 2020 Oct; Vol. 52 (8), pp. 2548-2550. Date of Electronic Publication: 2020 Jun 20.
DOI: 10.1016/j.transproceed.2020.01.124
Abstrakt: Background: Primary refractory acute myeloid leukemia (AML) is associated with dismal prognosis. No standard treatment options are available, and it remains an unmet clinical need. Here, we report a case of a tandem allogeneic hematopoietic stem cell transplantation (allo-HSCT) performed in a patient who did not achieve remission after 2 courses of induction chemotherapy.
Methods Case Report: The treatment was approved by the Bioethical Commission of the Medical University of Warsaw and was performed in accordance with the Declaration of Helsinki. The patient gave informed consent.
Results: A 41-year-old woman was diagnosed with AML, high cytogenetic risk, with concomitant skin and central nervous system involvement, bone marrow necrosis, and hemophagocytic lymphohistiocytosis. She received "3+7" induction and HAM (cytarabine, mitoxantrone) reinduction, after which she did not achieve remission and hematopoietic recovery. Tandem allo-HSCT was performed from the same HLA-identical brother---the first after reduced intensity conditioning (cladribine, cytarabine, mitoxantrone, melphalan) and the second after myeloablative conditioning (BuCy--busulphan, cyclophosphamide). The patient obtained complete remission after the first allo-HSCT and remains disease-free after the second for 5 years CONCLUSION: Tandem allo-HSCT may be a treatment option for primary refractory AML.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: